Altimmune (ALT) Debt Ratio (2012 - 2026)

Altimmune's (ALT) quarterly Debt Ratio came in at 0.1 in Q1 2026, down 16.07% on a QoQ basis from 0.12 in Q4 2025.

Altimmune (ALT) Debt Ratio (2012 - 2026) Analysis & Trends

Altimmune (ALT) has 14 years of Debt Ratio data on file, last reported at 0.1 in Q1 2026.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.1 in Q1 2026; TTM through Mar 2026 was 0.1, a N/A change from a year earlier, with the FY2025 full-year figure at 0.12, changed N/A from the prior year.
Debt Ratio for Q1 2026 stood at 0.1, down from 0.12 in the prior quarter.
Over the last five years, Debt Ratio for ALT reached as high as 0.12 in Q4 2025 and fell as low as 0.01 in Q2 2022.
Historically, Debt Ratio has averaged 0.05 across 4 years, with a median of 0.03 in 2023.
On a YoY basis, Debt Ratio climbed as much as 346.72% in 2022 and fell as far as 35.77% in 2022.
Year by year, Debt Ratio stood at 0.02 in 2022, then grew by 16.74% to 0.03 in 2023, then surged by 373.93% to 0.12 in 2025, then fell by 16.07% to 0.1 in 2026.
Per Business Quant data, the three most recent Debt Ratio figures were 0.1 in Q1 2026, 0.12 in Q4 2025, and 0.07 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Altimmune	7.96 Mn	7.96 Mn	-	0.10

Download Data